KnowBreastCancer StopBreastCancer Learn the Facts. Know the Evidence. Become an Advocate. Brought to you by NBCC

Category: Uncategorized

In mathematical modeling study, investigators find benefits outweigh risks of biennial mammograms for high-risk women in their 40s

A study published in Annals of Internal Medicine using mathematical modeling suggests looking at the level of risk for breast cancer for women in their 40s would aid in determining which women would benefit from mammography screening. In this study, investigators from the NCI’s Cancer Intervention and Surveillance Modeling Network (CISNET) used simulation models to […]

Brachytherapy may increase risk of mastectomy

Brachytherapy is associated with increased risk of subsequent mastectomy and more complications compared to whole-breast irradiation (WBI), according to a new study published in the Journal of the American Medical Association. Moreover, it did not improve survival. In recent years, use of breast brachytherapy, or an implanted radioactive source, after lumpectomy for early breast cancer […]

ACS publishes new guidelines for diet, exercise, and weight control for cancer survivors

New guidelines from the American Cancer Society (ACS) recommend that cancer survivors achieve and maintain a healthy weight, get enough exercise, and eat a healthy diet to improve their treatment outcomes, quality of life, and disease-free and overall survival. According to Colleen Doyle MS RD, ACS director of nutrition and physical activity and co-author of […]

Researchers Classify Breast Cancer Tumors Into Ten Distinct Subtypes

A study published this week in the journal Nature suggests that breast tumors can be classified into ten distinct subtypes, ranging from very treatable to extremely aggressive. This finding is a major step toward the goal of more tailored breast cancer treatments. In this study, led by researchers at the Cancer Research UK, scientists analyzed […]

Study Reports 15% to 25% of Breast Cancers Are Overdiagnosed

According to a new study out of Norway, about 15% to 25% of cases of breast cancer are overdiagnosed. Published today in the Annals of Internal Medicine, the study reports that 6 to 10 women were overdiagnosed for every 2,500 women invited to screen in the Norwegian Screening Program. Kalager et al. quantified the rate […]

Study suggests red wine may provide breast cancer benefit

Drinking red wine may decrease breast cancer risk, according to a study published this month in the Journal of Women’s Health. According to the researchers, chemicals in red grape skin and seeds may act as aromatase inhibitors (AIs) and decrease breast cancer risk in premenopausal women. Researchers at Cedars-Sinai Medical Center in Los Angeles, California […]

ACS predicts over 290,000 women and men to be diagnosed with in situ and invasive breast cancer in 2012

The American Cancer Society (ACS) estimates 229,060 women and men will be diagnosed with invasive breast cancer this year, and that 39,920 will die from the disease. In Cancer Facts & Figures 2012, released this week, the ACS also estimates 63,300 new cases of in situ breast cancer in women this year. Over 53,000 of […]

NIH Scientists Find Pathway to Regulate Cancer Growth and Metastasis in Mice

In a mouse study published this month in the Journal of Clinical Investigation, scientists from the National Institute of Environmental Health Sciences (NIEHS) present a novel way to prevent tumor metastasis by eliminating the blood vessels that feed the tumor. If the production of small molecules known as epoxyeicosatrienoic acids (EETs) is stopped, cancer cells […]

SABCS 2011: Exemestane Plus Everolimus Increased Progression-Free Survival for Women With Metastatic Breast Cancer

The combination of everolimus (Afinitor) and the aromatase inhibitor exemestane (Aromasin) improved progression-free survival in women diagnosed with metastatic breast cancer, according to results of the Breast Cancer Trials of Oral Everolimus (BOLERO-2). Results of a preplanned interim analysis of phase III clinical trial were published yesterday in the New England Journal of Medicine, and […]

SABCS 2011: Dual HER2 Blockade Significantly Extends Progression-Free Survival

Results of the CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) trial will be presented today at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium and are also published in the New England Journal of Medicine. These findings suggest that the combination of two HER2 blocking agents, trastuzumab and pertuzumab, when used with docetaxel, prolongs […]